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Abstract Lafora disease is a fatal autosomal recessive form of progressive myoclonus 
epilepsy. Patients manifest myoclonus and tonic-clonic seizures, visual hallucinations, 
intellectual and progressive neurologic deterioration beginning in adolescence. The two genes 
known to be involved in Lafora disease are EPM2A and NHLRC1 (EPM2B). The EPM2A 
gene encodes laforin, a dual-specificity protein phosphatase, and the NHLRC1 gene encodes 
malin, an E3-ubiquitin ligase. The two proteins interact with each other and, as a complex, are 
thought to regulate glycogen synthesis. Here, we report three Lafora families with two novel 
pathogenic mutations (C46Y and L261P) and two recurrent mutations (P69A and D146N) in 
NHLRC1. Investigation of their functional consequences in cultured mammalian cells 
revealed that malinC46Y, malinP69A, malinD146N and malinL261P mutants failed to downregulate 
the level of R5/PTG, a regulatory subunit of protein phosphatase 1 involved in glycogen 
synthesis. Abnormal accumulation of intracellular glycogen was observed with all malin 
mutants, reminiscent of the polyglucosan inclusions (Lafora bodies) present in patients with 
Lafora disease.  




Lafora disease (OMIM 254780) is an autosomal recessive, progressive myoclonus epilepsy 
that manifests during the first or second decade of life with myoclonic seizures, generalized 
tonic-clonic seizures and focal occipital seizures, followed by progressive central nervous 
system degeneration with severe motor and coordination disability, constant myoclonus, 
dementia and, finally, death within 10 years of onset [1]. The pathological hallmark of Lafora 
disease is the accumulation of polyglucosan (poorly branched and insoluble form of glycogen) 
inclusion bodies, called Lafora bodies, in the cytoplasm of both neuronal and non-neuronal 
cells. The diagnosis of the disease relies on clinical findings, presence of Lafora bodies based 
on axillary skin biopsy and genetic analysis. 
The vast majority  of Lafora disease cases (90%) are due to mutations in two genes: 
EPM2A, which encodes laforin, a member of the dual-specificity protein tyrosine phosphatase 
family [2, 3], and NHLRC1 (NHL repeat containing 1, EPM2B) [4], which encodes malin, a 
protein containing a zinc-binding RING finger motif with E3-ubiquitin ligase activity [5, 6]. 
Malin interacts with and polyubiquitinates laforin, leading to its degradation by the 
proteasome [5, 6]. Several groups have shown that the laforin-malin complex promotes 
ubiquitination and proteasome-dependent degradation of proteins involved in the regulation of 
glycogen biosynthesis, in particular protein targeting to glycogen, R5/PTG, a regulatory 
subunit of type 1 protein phosphatase [7-9]. An abnormal rise in the cellular levels of 
R5/PTG, due to loss or alteration of laforin or malin, leads to glycogen accumulation.  
We report here the clinical characteristics of three Lafora disease families with four 
NHLRC1 missense mutations (C46Y, P69A, D146N and L261P) and provide evidence that all 
mutations prevented the laforin-malin complex from downregulating R5/PTG-induced 
glycogen synthesis, thereby leading to glycogen accumulation. 
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Materials and methods 
Families and patients 
Twelve unrelated patients affected by Lafora disease were included in the mutational 
screening. We focused on families A, B and C which were investigated at Pitié-Salpêtrière, 
Necker-Enfants Malades and Nancy hospitals, respectively. Blood samples were obtained 
with signed informed consent and genomic DNA was extracted using standard procedures. 
NHLRC1 mutational screening 
Mutation analysis was performed in the index case of each the 12 families by direct 
sequencing of the NHLRC1 single coding exon. Primer sequences are available on request. 
PCR products were sequenced using the Big Dye Terminator Cycle sequencing kit on a 3710 
Applied Biosystems sequencer. Effect of mutations, including conservation of amino acids 
among species was evaluated using AlaMut-1.42 prediction software (Interactive 
Biosoftware, France). 
Cell culture and transfection 
The full-length human pEGFPC2-malin construct was kindly provided by Dr. S. Ganesh and 
was used for immunofluorescence experiments. Malin mutants (C46Y, P69A, D146N and 
L261P) were generated using the Quickchange ®II XL site-directed mutagenesis kit 
(Stratagene) and sequenced to confirm the correct incorporation of the mutation. To construct 
pFLAG-malin wild-type and mutant  plasmids, BglII/BamHI fragments from pEGFPC2-
malin containing plasmids were subcloned into pFLAG-CMV6 (Sigma). Other plasmids used 
in this study were pACT2-laforin, pCIneo-laforin and pCMV-HA-R5/PTG [10]. We used 
COS-7 cells for immunofluorescence experiments and human embryonic kidney (HEK293) 
cells for biochemistry and Western blotting. Both cell lines (COS-7 and HEK293) were 
cultured in Dulbecco’s modified Eagle’s medium containing 10% fetal bovine serum, 2 mM 
of L-Glutamine, 100 units/ml of penicillin and 100 µg/ml of streptomycin. All transient 
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transfections were performed using Lipofectamine 2000 according to the manufacturer’s 
recommendations (Invitrogen).  
Immunofluorescence 
COS-7 cells grown on chamber slides were rinsed with PBS and fixed for 20 min in PBS 
containing 4% paraformaldehyde. After fixation, cells were permeabilized with 0.2% Triton 
X-100 for 10 min, and blocked for 30 min with 10% goat serum. Cells were analyzed using 
GFP-derived fluorescence for observation of malin and incubated with anti-Myc antibody to 
label laforin (9E10, Santa Cruz Biotechnology). Finally, the glass slides were washed, air-
dried, and mounted with Mowiol. Immunofluorescence images were obtained using a laser 
scanning confocal microscope (Zeiss 510) with a 63X objective.  
RNA purification and retrotranscription 
Total RNAs were extracted from COS-7 cells with RNeasy minicolumns (Qiagen). 
Quantification was done spectrophotometrically at 260 nm. Up to 5 μg of total RNA from 
each sample were reverse transcribed for 50 min at 50ºC in a 20-μl reaction volume using 200 
units of Superscript® III Reverse Transcriptase (Invitrogen) in the presence of 50 ng random 
hexamers. Specific primers were designed to specifically amplify a fragment of 
approximately 100 bp from the 5’ region of the plasmid to the coding sequence of NHLRC1 
(5´CCGGACTCAGATCTCGAGCT3’ and 5´CTTCGGCCGCCATGG3’). 
Western blotting 
HEK293 cells were lysed 24 h after transfection, as previously described [10]. Total proteins 
(25 µg) from the soluble fraction of cell lysates were analyzed by SDS-PAGE and Western 
blotting using appropriate antibodies: mouse monoclonal anti-laforin [10], rabbit polyclonal 
anti-R5/PTG [10], mouse monoclonal anti-Flag (1/5000, Sigma), rabbit polyclonal anti-actin 
(1/4000, Sigma), rabbit anti-GFP (1/1000, ab290, Abcam) and monoclonal anti-α-tubulin 
(1/1000, Sigma). Immunoreactive bands were visualized using SuperSignal West Dura kit 
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following the manufacturer’s instructions (Thermo Scientific). Membranes were revealed on a 
KODAK Image Station 4000MM Digital Imaging System.  
Yeast two-hybrid assay  
The yeast two-hybrid system is based on the fact that the protein of interest (laforin) is 
expressed as a fusion protein to the DNA binding domain (DBD, here LexA) and the 
activation domain (AD) is fused to the second protein of interest (malin). Only if laforin and 
malin physically interact with one another are the DBD and AD brought together to activate 
expression of the downstream reporter gene (here lac Z which codes for the β-galactosidase). 
To construct wild-type and mutant (C46Y, P69A, D146N and L261P) pBTM116-malin 
plasmids, EcoRI fragments from pEGFPC2-malin plasmids replaced the EcoRI fragment 
present in plasmid pBTM116-malin [9]. The yeast CTY10.5d strain was co-transformed with 
combinations of pACT2-laforin and pBTM116-malin wild-type and mutants. Transformants 
were grown in selective SC medium and quantitative -galactosidase activity was assayed in 
permeabilized cells and expressed in Miller units. 
Glycogen determination 
Glycogen determination was carried out by homogenizing transfected HEK293 cells in ice-
cold 30% KOH and the extract was then heated at 100ºC for 15 min. Glycogen was then 
measured as previously described [9]. The amount of glycogen was expressed as the amount 
of released glucose per mg of total protein. 
Statistical analyses 
Values are given as means ± SEM (standard error of the mean) of at least three independent 
experiments. Differences between groups were analyzed by two-tailed Student’s t-tests. 




Clinical description of the families 
Family A members originated from a small village in Turkey (Fig. 1A, Table 1). The proband 
had normal birth and psychomotor development. Epilepsy began at 13 years of age with 
numerous generalized tonic clonic seizures, absences with eyelid myoclonia, fragmentary and 
multifocal, and bilateral massive myoclonus jerks. She never complained of visual 
hallucinations. Epilepsy was pharmacoresistant to polytherapy with valproate, phenobarbital 
and clonazepam. Intellectual decline appeared rapidly after the beginning of the disease. At 27 
years, the patient displayed major cognitive disturbances, aphasia and apraxia. Motor 
impairment was mainly due to cerebellar symptoms and myoclonus. Axillary skin biopsy was 
negative. The brother, who was 25 years old, was not examined but displayed similar 
symptoms starting in adolescence. Family B was of Russian origin (Fig. 1B, Table 1). The 
parents of the proband were not consanguineous. The proband was a 17-year-old girl with 
normal birth and psychomotor development. The disease began at 13 years of age with brief 
episodes of loss of contact associated with eyelid myoclonia. She started to present 
fragmentary and multifocal, as well as bilateral massive (both upper limbs) myoclonus jerks, 
sometimes causing her to fall. She had brief visual hallucinations while being treated with 
ethosuximid. School difficulties and depressive symptoms progressively appeared. 
Generalized tonic-clonic seizures on awakening started a few years later. At last follow-up 
examination, the patient was continuing to suffer from fragmentary and massive myoclonus, 
occasional tonic-clonic seizures and major cognitive deficiency. 
Family C, of Ukrainian/French origin, was recently described [11] (Fig. 1C, Table 1). This 
patient had normal birth and psychomotor development. She experienced a first generalized 
tonic-clonic seizure at 14 years of age. Neuropsychological examination showed a 
heterogeneous profile with major impairment of non verbal performance, including 
8 
 
impairment of attention, memorization and visuo-spatial skills. The patient was 
pharmacoresistant with fragmentary and bilateral massive myoclonus jerks and frequent loss 
of contact and photosensitive generalized seizures. Cognitive and motor abilities declined 
progressively. At age 16, she had a very poor language with complete loss of autonomy, 
weight loss and was sleeping most of the day. She died from cardiovascular failure in 
intensive care for refractory status epilepticus. Axillary skin biopsy showed typical Lafora 
bodies. 
Identification of NHLRC1 mutations 
We performed sequence analysis of the NHLRC1 gene in the index cases belonging to a 
cohort of 12 families with Lafora disease. None of these patients harbored mutations in the 
coding region of the EPM2A gene. In both affected individuals of Family A, we identified the 
c.436G>A missense mutation at the homozygous state resulting in the previously reported 
p.Asp146Asn/D146N mutation [4, 12, 13] (Fig. 1A). The patient in Family B was a 
compound heterozygote for two distinct missense mutations: (i) a novel sequence variant 
c.782T>C resulting in p.Leu261Pro/L261P and (ii) a second nucleotide change c.436G>A 
resulting in p.Asp146Asn/D146N (Fig. 1B). The L261P variant has not been described before 
and most likely represents a novel mutation responsible for Lafora disease since it was not 
found in 170 Caucasian and 84 North African controls. Since DNA of the parents was not 
available, we cloned the NHLRC1 ORF from the lymphoblasts of the patient and confirmed 
that L261P and D146N variants were located on two distinct alleles, suggesting that the 
parents were heterozygous for each mutation. The patient in Family C was a compound 
heterozygote for two missense mutations: c.137G>A resulting in p.Cys46Tyr/C46Y and 
c.205C>G resulting in p.Pro69Ala/P69A (Fig. 1C). While P69A results from a recurrent 
mutational event reported in numerous Lafora disease families [4, 13, 14], C46Y mutation is a 
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recently reported novel mutation [11], which was absent from 110 control individuals of same 
ethnic origin.  
The two mutations C46Y and P69A were located in the RING domain mediating E3 
ubiquitin ligase activity, while the other two, D146N and L261P, were located in NHL 
domains (Fig. 2A). All four amino acid residues affected by the missense mutations identified 
in the present study were highly conserved across a broad range of different NHLRC1 
orthologous proteins, reflecting the evolutionary constraint placed on these residues (Fig. 2B). 
We therefore considered them to be pathogenic mutations.  
Expression levels of malin mutants are similar to wild-type 
We next analyzed the mRNA and protein profile of malinC46Y, malinP69A, malinD146N, 
malinL261P and wild-type malin. COS-7 cells were transiently transfected with equal amounts 
of plasmids and, 24 h later, RNAs from cell lysates were analyzed by RT-PCR. As shown in 
Fig. 3, C46Y, P69A, D146N and L261P disease-causing mutations did not cause major 
alterations of the malin transcript (upper panel). We also analyzed the protein levels of wild-
type and mutant forms of malin by Western blot. The expression constructs encoding GFP-
tagged malin and the four mutant forms produced fusion proteins of expected size. As shown, 
the steady-state levels of expression of malinC46Y, malinP69A, malinD146N, malinL261P and wild-
type were similar, suggesting that all mutants had normal conformation and were stable in 
COS-7 cells (Fig. 3, bottom panels). 
Subcellular distribution of malin mutants is similar to wild-type 
We examined the subcellular localization of wild-type and Lafora disease-causing mutant 
forms of malin in transfected COS-7 cells by fluorescence imaging. Overexpressed GFP-
tagged malin was observed in the cytoplasm of cells, predominantly in a diffuse manner (Fig. 
4A) but also as a punctate perinuclear staining in ~15% of cells (Fig. 4B), or as a large 
aggregate in a small proportion of cells (~8%) (Fig. 4C). Large aggregates were present in 
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apparently healthy cells, presenting an intact DAPI-labeled nucleus as reported in another 
study [15]. Expression of GFP-malin at low levels (5 times less transfected plasmid) caused a 
similar proportion of cells containing aggregates, suggesting that it is not a consequence of 
overexpression (data not shown).  
Next, we analyzed the subcellular distribution and aggregate formation of the pathogenic 
malinC46Y (Fig. 4 D-F), malinP69A (Fig. 4 G-I), malinD146N (Fig. 4 J-L) and malinL261P mutants 
(Fig. 4 M-O). The subcellular distribution and aggregation profile of these mutant proteins 
were similar to those of wild-type malin. Among three independent experiments, there was no 
statistical difference in proportion between the number of cells with diffuse versus punctated 
and aggregated malin between malinC46Y, malinP69A, malinD146N, malinL261P and wild-type 
protein (Fig. 4P).  
We also examined the co-localization of malin with its interacting partner laforin (Fig. 5). 
Both wild-type malin and laforin were co-localized in a diffuse and punctate manner in the 
cytoplasm of the transfected cells (Fig. 5C). All four malin mutants also co-localized with 
laforin in the cytoplasm of COS-7 cells (Fig. 5F, I, L, O).  
Impaired interaction of malin mutants with laforin in yeast two-hybrid assay 
We next performed a yeast two-hybrid assay to examine the ability of malin mutants to 
interact with laforin. With this aim, we constructed pBTM116-malin plasmids (wild-type and 
C46Y, P69A, D146N and L261P mutants) that produced LexA-malin fusion proteins. As we 
previously reported [9], wild-type malin interacted with laforin. However, all four malin 
mutations caused a severe decrease of interaction with laforin (Fig. 6A), although we 
observed a residual interaction between laforin and malinP69A and malinD146N. The differences 
in protein-protein interaction between mutants and wild-type were not due to different 




Downregulation of R5/PTG is impaired by malin mutations 
Since the laforin-malin complex downregulates R5/PTG-induced glycogenesis [9], we 
investigated the ability of disease-causing malin mutations to degrade the R5/PTG protein. 
HEK293 cells were co-transfected with Flag-malin, pCIneo-laforin and pCMV-HA-R5/PTG, 
and proteins were analyzed by Western blot. As expected, co-expression of laforin and wild-
type malin with R5/PTG resulted in a marked reduction of R5/PTG levels in comparison with 
cells that did not overexpress laforin and malin (Fig. 7A). In contrast, the co-expression of 
laforin with either malinC46Y, malinP69A, malinD146N or malinL261P caused an accumulation of 
R5/PTG in the cells (Fig. 7A). As illustrated in Fig. 7B, quantification by densitometry of the 
relative levels of R5/PTG revealed a statistically significant difference between wild-type and 
mutant forms of malin. Increased levels of R5/PTG suggest that overproduced malin mutants 
could not form a functional complex with laforin to mediate ubiquitin-dependent proteasomal 
degradation of R5/PTG.  
Malin mutations lead to glycogen accumulation 
We next measured the impact of malin pathogenic mutations on the glycogenic capacity of 
R5/PTG protein. The co-transfection of laforin with wild-type malin led to a marked decrease 
of glycogen levels in HEK293 cells expressing R5/PTG compared to cells overexpressing 
only R5/PTG (Fig. 8). This result is consistent with the fact that the laforin-malin complex 
downregulates R5/PTG via a proteasomal degradation pathway. In contrast, malinC46Y, 
malinP69A, malinD146N and malinL261P mutants all failed to reduce glycogen levels. As 
illustrated in Fig. 8, accumulation of glycogen levels was detected in cells expressing malin 




In this paper we have described three families with Lafora disease mutated in the NHLRC1 
gene and investigated the functional impact of the corresponding mutations. We identified 
four pathogenic mutations in NHLRC1: the novel mutation L261P, the recently reported 
mutation C46Y and two recurrent missense mutations, P69A and D146N. We first aimed to 
assess by fluorescence imaging the impact of these mutations on the subcellular targeting of 
GFP-tagged malin in transfected COS-7 cells. In accordance with previous studies [4-6, 16], 
we observed that the wild-type malin protein displayed a diffuse cytoplasmic expression 
pattern with small punctate inclusions or large aggregates in some cells. A thorough analysis 
of the cellular localization of the disease-causing malinC46Y, malinP69A, malinD146N and 
malinL261P mutants showed that all presented a similar expression pattern to that of wild-type 
malin. The effect of Lafora disease-associated malin mutations on cellular localization is 
known to be heterogeneous since a fraction of NHLRC1 missense mutations alter the 
subcellular localization of malin, while others have no effect [16, 17]. In our experimental 
conditions, C46Y, P69A, D146N and L261P mutations did not impair the subcellular 
targeting of GFP-tagged malin protein and all co-localized with laforin similarly to wild-type 
malin, confirming that alteration of the subcellular localization is not a mechanism common 
to all NHLRC1 mutations. We then assessed by a yeast two-hybrid assay the interaction with 
laforin and provide evidence that all four mutations affected the physical interaction with 
laforin, suggesting that disease-causing mutations might prevent the formation of a laforin-
malin complex. Surprisingly, mutations in the RING domain of malin (C46Y and P69A), 
impaired interaction with laforin, similarly as mutations in the NHL domains (D146N and 
L261P), probably due to perturbation in the overall conformation of the protein. Since a 
number of laforin-malin interaction partners involved in the glycogenesis might be affected 
by malin mutations, we investigated whether the pathogenic mutations of malin could affect 
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glycogen synthesis pathway. A key positive regulator of glycogen synthesis is R5/PTG, a 
subunit of protein phosphatase 1, which is downregulated by the laforin-malin complex via 
ubiquitination and proteasome-dependent degradation. First, we investigated the capacity of 
malin mutants to regulate R5/PTG levels in HEK293 cells simultaneously overexpressing 
laforin, malin and R5/PTG. Our results revealed that levels of R5/PTG in cells expressing 
malinC46Y, malinP69A, malinD146N and malinL261P mutants concomitantly with laforin were 
increased, consistent with an absence of degradation of R5/PTG. Impairment of the 
interaction between malin and laforin probably precludes the action of malin on its substrate 
R5/PTG. We next measured the levels of intracellular glycogen and observed that all disease-
causing mutations caused a marked increase in glycogen level. Since overexpression of 
R5/PTG results in glycogen accumulation [9], we speculate that accumulation of glycogen 
with mutant forms of malin is likely due to the lack of downregulation of R5/PTG levels. 
However, the impairment of the laforin-malin interaction probably causes the loss of 
interaction with other partners of the glycogen synthesis pathway, including the muscle 
glycogen synthase, which could also lead to a glycogen accumulation [7]. Vilchez et al. had 
reported a similar observation for D146N mutation [7] and we provide evidence here that 
accumulation of glycogen is likely to be a frequent consequence of NHLRC1 mutations. An 
epm2b-/- knockout mouse was recently reported to display higher levels of glycogen in 
skeletal muscle, liver and brain, which is consistent with malin having a critical role in the 
regulation of glycogen metabolism [18, 19]. In the present study, while all four NHLRC1 
mutations had similar consequences for glycogen levels of transfected cells, they were not all 
associated with the positive finding of Lafora polyglucosan bodies. Indeed, the skin biopsy of 
the patient harboring both C46Y and P69A mutations (Family C) revealed the presence of 
Lafora bodies, whereas the patient harboring the D146N mutation (Family A) was negative 
for Lafora bodies. The patient with D146N and L261P mutations (Family B) could not be 
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tested (Table 1). Since all mutations led to an in vitro increase of glycogen levels, we can 
speculate that Lafora bodies may have been missed due to a high false-negative rate of skin 
biopsy in Lafora disease [11]. This may well have been the case with the patient with the 
D146N mutation, since Lafora bodies were reported to be present in other patients with the 
same mutation at the homozygous state [12, 13]. Interestingly, several groups have reported 
that the D146N mutation in NHLRC1 is associated with a milder clinical course with late age 
at onset and slow progression of disease [12-14]. We also noticed that the disease course was 
longer (14 years at the time of the study) in the index case of Family A with the D146N 
mutation at the homozygous state, compared to the patient of Family B who was compound 
heterozygote for the D146N and L261P mutations. A possible explanation for the milder 
severity of the disease in patients carrying a homozygous malin D146N mutation could be 
that the enzymatic activity of the D146N variant is still preserved, at least for some substrates, 
consistent with previous in vitro results indicating that purified malin D146N retained E3-
ubiquitin ligase activity [9].The patient in Family C had an unusually fast disease progression. 
Since the P69A mutation, which has been reported in many patients of Southern European 
descent, was not shown to be associated with an unusual Lafora phenotype [14], we can 
hypothesize that the C46Y mutation played a role in the rapid disease course of this patient. It 
would suggest the existence of possible phenotype-genotype correlations for some mutations 
at the homozygous state. However, this notion will need to be confirmed in a larger number of 
families.  
In conclusion, we have functionally characterized four disease-causing mutations in 
NHLRC1, two of which were recurrent (P69A and D146N) and two were novel (C46Y and 
L261P). Our data reveal that the major and common effect of these variants, irrespective of 
their position in the protein (RING domain or NHL domains) is to lead to an accumulation of 
intracellular glycogen that could be the cause of the formation of Lafora bodies in patients.  
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Figure 1. Identification of NHLRC1 mutations. (A) Segregation of the c.436G>A 
(p.Asp146Asn/D146N) mutation in Family A. Arrow indicates the index case, dashed line 
indicates probable consanguinity. (B) Detection of c.782T>C (p.Leu261Pro/L261P) and 
c.436G>A (p.Asp146Asn/D146N) mutations in patient of Family B. (C) Segregation of 
c.137G>A (p.Cys46Tyr/C46Y) and c.205C>G (p.Pro69Ala/P69A) mutations in Family C. * 
indicates DNA sample available for the study.  
Figure 2. Representation of malin showing mutations (A) Schematic representation 
showing domain organization and location of the mutations of the malin protein. (B) Multiple 
protein alignment of malin showing conservation of Cys46, Pro69, Asp146 and Leu261 
residues in different vertebrates.  
Figure 3. Expression levels of mutants of malin. COS-7 cells were transiently transfected 
with the wild-type (WT) or indicated mutant GFP-Malin-expressing plasmids. Upper panel: 
RT-PCR products of exogenous wild-type and mutants of malin separated on a 1.5% agarose 
gel. All mRNA transcripts were detected in comparable amounts. Bottom panel: Detection of 
wild-type and mutants of malin by Western blot with anti-GFP antibody. Equal amounts of 
proteins were loaded as shown by the α-tubulin control. 
Figure 4. Subcellular distribution of malin mutants. COS-7 cells were transiently 
transfected with the wild-type (WT) or indicated mutant GFP-Malin-expressing plasmids. 
Malin was detected with a confocal microscope using the GFP-derived fluorescence and 
nuclei were stained with DAPI. All malin variants showed a cytoplasmic localization, either 
as a diffuse or punctate staining or as large aggregates. Most representative localizations of 
wild-type (WT) malin (A-C), C46Y (D-F), P69A (G-I), D146N (J-L) and L261P (M-O) 
mutants are shown. Magnification bars: 10µm (P) Histograms showing the percentage of cells 
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in each experiment (WT: n=1140; C46Y: n=1247; P69A: n=1262; D146N: n=1306; L261P: 
n=1145 cells, bars indicate SEM of three independent transfections).  
Figure 5. Malin mutants colocalize with laforin. COS-7 cells were transiently co-
transfected with the GFP-malin and laforin-Myc plasmids. Direct visualization of GFP-malin 
(in green) and immunofluorescence with anti-Myc (in red) was performed. Most 
representative localizations with wild-type (WT) malin (A-C), C46Y (D-F), P69A (G-I), 
D146N (J-L) and L261P (M-O) mutants are shown. Magnification bars: 10µm 
Figure 6. Malin mutations affect yeast two-hybrid interaction with laforin. Yeast 
CTY10.5d cells were co-transformed with plasmids pBTM116-malin (WT or indicated 
mutants) or empty vector (pBTM116) and plasmid pACT2-laforin. (A) Protein interaction 
was estimated using the yeast two-hybrid system, by measuring the β-galactosidase activity. 
Values correspond to means from 4-6 different transformants (bars indicate SEM). (B) 
Western blot analysis indicated that all proteins were expressed at similar levels. 
Figure 7. Malin mutations do not downregulate R5/PTG protein levels. HEK293 cells 
were co-transfected with pCMV-HA-R5/PTG, pCIneo-laforin and pFLAG-Malin wild-type 
(WT) or different mutant plasmids. (A) Twenty-four hours after transfection, cell extracts (25 
μg) were analyzed by Western blotting using anti-R5/PTG, anti-laforin, anti-Flag and anti-
actin antibodies. (B) Relative intensity of the R5/PTG bands was normalized to the actin 
levels and referred to the levels found in cells only expressing R5/PTG. Bars indicate SEM of 
three independent experiments: ** p<0.01 and *** p<0.001. 
Figure 8. Malin mutations do not downregulate the glycogenic activity of R5/PTG. 
Glycogen levels were measured in transfected HEK293 cells with pCMV-HA-R5/PTG, 
pCINEO-laforin and pFLAG-Malin wild-type (WT) or different mutant plasmids. Values 
22 
 
were referred to those found in cells expressing only HA-R5/PTG. Bars indicate SEM of three 
independent experiments. ** p<0.01. 
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